Comparing 0 vendors in Viral Vector and Plasmid DNA Manufacturing across 0 criteria.
Contenders
Emerging Companies
Become a Client
- Access Exclusive Reports, expert insights and tailored support to drive growth.
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
2.1 DRIVERS
2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases
2.1.2 Availability of funding for development of gene therapy
2.1.3 Effectiveness of viral vectors
2.1.4 Ongoing research on viral vector-based gene and cell therapies
2.2 RESTRAINTS
2.2.1 High operational costs associated with cell and gene therapy manufacturing
2.2.2 Short shelf life of viral vectors
2.3 OPPORTUNITIES
2.3.1 Smart capital deployment and planning for scalability
2.3.2 Leveraging digital tools to facilitate operational excellence
2.4 CHALLENGES
2.4.1 Risk of mutagenesis and other unwanted outcomes
2.4.2 Individual optimization and low yield
3.1 INTRODUCTION
3.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
3.3 MARKET SHARE ANALYSIS
3.4 REVENUE SHARE ANALYSIS
3.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
3.5.1 STARS
3.5.2 EMERGING LEADERS
3.5.3 PERVASIVE PLAYERS
3.5.4 PARTICIPANTS
3.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
3.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
3.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
3.7 COMPETITIVE SCENARIO AND TRENDS
3.7.1 PRODUCT & SERVICE LAUNCHES
3.7.2 DEALS
3.7.3 OTHERE DEVELOPMENTS
4.1 KEY PLAYERS
4.1.1 LONZA GROUP
4.1.1.1 Business overview
4.1.1.2 Products & services offered
4.1.1.3 Recent developments
4.1.1.4 MnM view
4.1.2 MERCK KGAA
4.1.2.1 Business overview
4.1.2.2 Products & services offered
4.1.2.3 Recent developments
4.1.2.4 MnM view
4.1.3 THERMO FISHER SCIENTIFIC INC.
4.1.3.1 Business overview
4.1.3.2 Products & services offered
4.1.3.3 Recent developments
4.1.3.4 MnM view
4.1.4 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
4.1.4.1 Business overview
4.1.4.2 Products & services offered
4.1.4.3 Recent developments
4.1.5 CATALENT, INC.
4.1.5.1 Business overview
4.1.5.2 Products & services offered
4.1.5.3 Recent developments
4.1.6 WUXI APPTEC CO., LTD.
4.1.6.1 Business overview
4.1.6.2 Products & services offered
4.1.6.3 Recent developments
4.1.7 FUJIFILM CORPORATION
4.1.7.1 Business overview
4.1.7.2 Products & services offered
4.1.7.3 Recent developments
4.1.8 GENSCRIPT BIOTECH CORPORATION
4.1.8.1 Business overview
4.1.8.2 Products & services offered
4.1.8.3 Recent developments
4.1.9 TAKARA BIO INC.
4.1.9.1 Business overview
4.1.9.2 Products & services offered
4.1.9.3 Recent developments
4.1.10 OXFORD BIOMEDICA
4.1.10.1 Business overview
4.1.10.2 Products & services offered
4.1.10.3 Recent developments
4.1.11 NOVARTIS AG
4.1.11.1 Business overview
4.1.11.2 Products & services offered
4.1.11.3 Recent developments
4.1.12 PRECISION BIOSCIENCES
4.1.12.1 Business overview
4.1.12.2 Products & services offered
4.1.12.3 Recent developments
4.1.13 BLUEBIRD BIO, INC.
4.1.13.1 Business overview
4.1.13.2 Products & services offered
4.1.14 SARTORIUS AG
4.1.14.1 Business overview
4.1.14.2 Products & services offered
4.1.14.3 Recent developments
4.1.15 DANAHER CORPORATION
4.1.15.1 Business overview
4.1.15.2 Products & services offered
4.1.15.3 Recent developments
4.1.16 SIRION BIOTECH
4.1.16.1 Business overview
4.1.16.2 Products & services offered
4.1.16.3 Recent developments
4.2 OTHER PLAYERS
4.2.1 VGXI, INC.
4.2.2 KANEKA EUROGENTEC S.A.
4.2.3 PLASMIDFACTORY GMBH
4.2.4 ADDGENE
4.2.5 CELL AND GENE THERAPY CATAPULT
4.2.6 BATAVIA BIOSCIENCES B.V.
4.2.7 ALTOGEN BIOSYSTEMS
The Viral Vector & Plasmid DNA Manufacturing Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Viral Vector & Plasmid DNA Manufacturing. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 40 companies of which the Top 24 Viral Vector & Plasmid DNA Manufacturing Companies were categorized and recognized as the quadrant leaders.
Viral vectors are highly effective tools for delivering therapeutic genes to target cells in gene therapy. Their efficiency depends on several factors, including the type of virus used, the target cell type, the dosage and delivery method, and the patient's immune response. Currently, viral vectors are considered the most effective method for gene delivery, particularly for in vivo applications. Due to their natural tropism for specific cell types, viruses are well-suited for therapeutic purposes. Additionally, viral vectors can be engineered to meet specific requirements, offering significant advantages in targeting and entering cells for therapeutic applications.
The 360 Quadrant maps the Viral Vector & Plasmid DNA Manufacturing companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Viral Vector & Plasmid DNA Manufacturing quadrant. The top criteria for product footprint evaluation included Type (Viral Vectors and Plasmid DNA), Workflow(Upstream Manufacturing and Downstream Manufacturing), Application(Cell and Gene Therapy, Vaccine Development and Research), Disease Indication(Cancer, Genetic Disorders, Infectious Diseases and Others).
Key Players:
Some of the prominent players are Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), Catalent Inc. (US), WuXi AppTec (China), FUJIFILM Corporation (Japan), GenScript Biotech Corporation (US), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Novartis AG (Switzerland), Precision Biosciences (US), Bluebird Bio, Inc. (US), Sartorius AG (Germany), Danaher Corporation (US), SIRON Biotech (Germany), VGXI, Inc. (US), Waisman Biomanufacturing (US), Kaneka Eurogentec S.A. (Belgium), PlasmidFactory GmbH (Germany), ATUM (US), Addgene (US), Cell and Gene Therapy Catapult (UK), Batavia biosciences (Netherlands), and Altogen Biosystems (US). These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.- Viral vectors are engineered viruses used to deliver genetic material into cells in gene therapy, vaccine production, and other applications.
- Plasmid DNA is circular DNA that serves as a key starting material for producing viral vectors and is used in therapeutic applications, vaccine development, and research.
- Gene therapy for inherited and acquired diseases.
- Vaccine development, such as mRNA vaccines for infectious diseases.
- Cancer immunotherapy and oncolytic virus therapy.
Plasmid DNA is a critical raw material used in the production of viral vectors. It provides the genetic template required for the viral vector's functionality.
- Adenoviral vectors
- Adeno-associated viral (AAV) vectors
- Lentiviral vectors
- Retroviral vectors
The process must comply with standards set by regulatory agencies like the FDA, EMA, and ICH, focusing on Good Manufacturing Practices (GMP) to ensure product safety, efficacy, and quality.
- Identity and purity testing of plasmid DNA and viral vectors.
- Sterility testing.
- Assessment of potency, genetic stability, and absence of contaminants like endotoxins.
The Full List
